Open Access Green as soon as Postprint is submitted to ZB.
Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm.
Microb. Pathog. 170:105704 (2022)
Patients with SARS-CoV-2 infection, exhibit various clinical manifestations and severity including respiratory and enteric involvements. One of the main reasons for death among covid-19 patients is excessive immune responses directed toward cytokine storm with a low chance of recovery. Since the balanced gut microbiota could prepare health benefits by protecting against pathogens and regulating immune homeostasis, dysbiosis or disruption of gut microbiota could promote severe complications including autoimmune disorders; we surveyed the association between the imbalanced gut bacteria and the development of cytokine storm among COVID-19 patients, also the impact of probiotics and bacteriophages on the gut bacteria community to alleviate cytokine storm in COVID-19 patients. In present review, we will scrutinize the mechanism of immunological signaling pathways which may trigger a cytokine storm in SARS-CoV2 infections. Moreover, we are explaining in detail the possible immunological signaling pathway-directing by the gut bacterial community. Consequently, the specific manipulation of gut bacteria by using probiotics and bacteriophages for alleviation of the cytokine storm will be investigated. The tripartite mutualistic cooperation of gut bacteria, probiotics, and phages as a candidate prophylactic or therapeutic approach in SARS-CoV-2 cytokine storm episodes will be discussed at last.
Impact Factor
Scopus SNIP
Altmetric
3.848
1.076
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Review
Keywords
Bacteriophage ; Cytokine Storm ; Gut Bacteria ; Probiotics ; Sars-cov2 ; Signaling Pathways
Language
english
Publication Year
2022
HGF-reported in Year
2022
ISSN (print) / ISBN
0882-4010
e-ISSN
1096-1208
Journal
Microbial pathogenesis
Quellenangaben
Volume: 170,
Article Number: 105704
Publisher
Elsevier
Publishing Place
Oxford
Reviewing status
Peer reviewed
Institute(s)
Institute of Virology (VIRO)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-554300-001
WOS ID
WOS:000891382600006
Scopus ID
85135853671
PubMed ID
35948266
Erfassungsdatum
2022-11-09